Published: 27 January 2024
Author(s): Giuseppe Boriani, Luigi Gerra, Davide A Mei, Niccolo’ Bonini, Marco Vitolo, Marco Proietti, Jacopo F Imberti
Issue: May 2024
Section: Clinical Insights

Atrial fibrillation (AF) may be asymptomatic and the extensive monitoring capabilities of cardiac implantable electronic devices (CIEDs) revealed asymptomatic atrial tachi-arrhythmias of short duration (minutes-hours) occurring in patients with no prior history of AF and without AF detection at a conventional surface ECG. Both the terms “AHRE” (Atrial High-Rate Episodes) and subclinical AF were used in a series of prior studies, that evidenced the association with an increased risk of stroke. Two randomized controlled studies were planned in order to assess the risk-benefit profile of anticoagulation in patients with AHRE/subclinical AF: the NOAH and ARTESiA trials.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.